FDA meetings are pivotal moments in drug development. Type B and Type C interactions clarify FDA’s current expectations and inform both development planning and future labeling strategy. Yet many sponsors approach them with diffuse agendas, unfocused questions, or briefing books that leave reviewers working to discern the central scientific and regulatory story. Effective meetings start with a defined decision, bounded questions, and evidence organized so reviewers can understand the program in minutes, not hours.
HIC prepares you for regulatory meetings with the same discipline FDA brings to its reviews. Senior regulatory leads and former FDA meeting chairs work directly with your team to define the objective, frame questions that can realistically be answered, and build a briefing package that aligns data to proposed positions. We run realistic rehearsals so sponsors, clinicians, biostatisticians, and CMC leads can practice handling difficult questions and staying grounded in the written record. After the meeting, we analyze minutes, resolve ambiguities with the Agency when appropriate, and translate the outcome into tracked actions for protocols, studies, and submission plans so the discussion moves the program forward.
Meetings that advance your drug program
- We clarify the purpose of each FDA interaction and shape focused questions that elicit specific, actionable guidance
- Our advisors, including former FDA officials who have led and evaluated sponsor meetings, design briefing materials and talking points that align with reviewer logic
- We conduct targeted rehearsal sessions that pressure test answers, align messaging across functions, and prepare your team to perform under scrutiny
- Post-meeting, we convert minutes into a concrete action plan with owners and timelines, keeping your development and regulatory strategy aligned with the agreed path forward
